These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27611656)

  • 21. Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.
    Tartaglia A; Portela-Gomes GM; Oberg K; Vezzadini P; Foschini MP; Stridsberg M
    Virchows Arch; 2006 Apr; 448(4):399-406. PubMed ID: 16408221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity.
    Bandyopadhyay GK; Mahata SK
    Front Endocrinol (Lausanne); 2017; 8():20. PubMed ID: 28228748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The associations between anxiety/depression and plasma chromogranin A among healthy workers: Results from EHOP study.
    Li Y; Song Y; Dang W; Guo L; Xu W
    J Occup Health; 2020 Jan; 62(1):e12113. PubMed ID: 32515855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
    Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic effects and mechanism of action of the chromogranin A-derived peptide pancreastatin.
    Sánchez-Margalet V; González-Yanes C; Najib S; Santos-Alvarez J
    Regul Pept; 2010 Apr; 161(1-3):8-14. PubMed ID: 20184923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromogranin A as a biomarker in cardiovascular disease.
    Goetze JP; Alehagen U; Flyvbjerg A; Rehfeld JF
    Biomark Med; 2014; 8(1):133-40. PubMed ID: 24325234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study.
    Bachetti T; Ferrari Bardile A; Aloi TL; Colombo B; Assi E; Savino G; Vercelli A; Colombo R; Corti A
    Int J Cardiol; 2017 Jun; 236():438-443. PubMed ID: 28190616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chromogranin A (CgA) - characteristic of the currently available laboratory methods and conditions which can influence the results].
    Glinicki P; Jeske W
    Endokrynol Pol; 2009; 60(5):415-9. PubMed ID: 19885814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromogranin A.
    Hendy GN; Bevan S; Mattei MG; Mouland AJ
    Clin Invest Med; 1995 Feb; 18(1):47-65. PubMed ID: 7768066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromogranin A-derived peptides pancreastatin and catestatin: emerging therapeutic target for diabetes.
    Garg R; Agarwal A; Katekar R; Dadge S; Yadav S; Gayen JR
    Amino Acids; 2023 May; 55(5):549-561. PubMed ID: 36914766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
    Rustagi S; Warner RR; Divino CM
    J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion.
    Fasciotto BH; Trauss CA; Greeley GH; Cohn DV
    Endocrinology; 1993 Aug; 133(2):461-6. PubMed ID: 8344192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
    Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
    J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catestatin and vasostatin concentrations in healthy dogs.
    Srithunyarat T; Hagman R; Höglund OV; Olsson U; Stridsberg M; Jitpean S; Lagerstedt AS; Pettersson A
    Acta Vet Scand; 2017 Jan; 59(1):1. PubMed ID: 28049540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
    Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
    J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromogranin A plasma concentration and expression in pancreatic islet cell tumors of dogs and cats.
    Myers NC; Andrews GA; Chard-Bergstrom C
    Am J Vet Res; 1997 Jun; 58(6):615-20. PubMed ID: 9185968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromogranin A and the endothelial barrier function.
    Corti A; Ferrero E
    Curr Med Chem; 2012; 19(24):4051-8. PubMed ID: 22834794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
    Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
    Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
    Conlon JM
    Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.